As of 2026-08-07 · Last updated: 2026-08-09 · Source: SEC EDGAR (10-K), stockanalysis (5-year financials), TradingView (price, financials, consensus), Company IR · Prices & financials updated periodically (not real-time) · Information tool (not investment advice)
Debt burden is moderate, so it can be affected by the economic cycle.
Metrics · D/E ~162% · Current Ratio 1.35
💲Is the price expensive now?
On the expensive side
Even accounting for growth expectations, the price is set high.
Metrics · P/E 40.3 · P/B 42.2
💡Hyper-growth GLP-1 pharma (Zepbound, Mounjaro): TTM revenue +50%, 50% operating margin, 102% ROE. Debt is moderate, but ~40x P/E and P/B price in growth.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: TradingView (margins, debt, liquidity, P/B are TTM), as of 2026-08-07
Business Summary · Key Value Metrics
A global pharma company in diabetes and obesity (Mounjaro, Zepbound) plus oncology, immunology, and neuroscience. Explosive GLP-1 growth pushed TTM (2026) revenue to $79.7B. Q2 2026 revenue $23.0B (+48%) and non-GAAP EPS $8.38 (+33%) beat estimates; FY2025 revenue $65.2B with a 40.3% operating margin (note: TTM operating margin 49.7%).
Eli Lilly is growing explosively in GLP-1 obesity and diabetes therapies (tirzepatide: Mounjaro, Zepbound), forming a duopoly with Novo Nordisk. Its moat rests on dual-receptor technology, a deep late-stage pipeline (donanemab for Alzheimer's, oral GLP-1 orforglipron), and large-scale manufacturing investment. TTM operating margin is 49.7% (source: company IR, TradingView).
GLP-1 Market Lead
Mounjaro and Zepbound are surging in obesity and diabetes, forming a duopoly with Novo Nordisk.
Pipeline Depth
A deep late-stage pipeline, including donanemab (Alzheimer's) and oral orforglipron (obesity).
Manufacturing Moat
A $9B+ GLP-1 capacity buildout; production capacity itself is a barrier to entry.
Brand and R&D
140 years in pharma, with a physician-patient network and an R&D culture.
10-Year Financial Trends
Revenue's 9-year CAGR is +13.3%, but GLP-1 has accelerated it lately—+32% in 2024 and +45% in 2025, reaching $65.2B. Q2 2026 (reported Aug 5) revenue was $23.0B (+48%) with diluted EPS of $7.94 reported and $8.38 non-GAAP (+33%) — an earnings beat led by Mounjaro (+91%, $9.9B) and Zepbound (+46%, $4.9B). The oral obesity pill Foundayo (U.S. approval in April) contributed $98M in its first quarter, and EPS included $3.03 of acquired IPR&D charges (vs $0.14 a year ago). Lilly raised 2026 revenue guidance to $85-87B from $82-85B (source: company IR Aug 5 · SEC EDGAR 10-K · stockanalysis).
10-Year Growth
Revenue$65.2B · CAGR +13.3%
Operating Income$26.3B · CAGR +42.6%
EPS$23.00 · CAGR +27.5%
10-Year Valuation
P/E (year-end)46.8x · avg 62.3x
ROE101.2% · avg 74.2%
Operating Margin40.3% · avg 27.1%
📊 Annual Data Table (LLY) — expand/collapse
Year
Revenue (B$)
Op. Income (B$)
EPS ($)
P/E (x)
ROE (%)
Op. Margin (%)
2016
21.2
—
2.59
—
—
—
2017
22.9
—
-0.19
—
—
—
2018
24.6
—
3.14
—
—
—
2019
22.3
—
8.93
—
—
—
2020
24.5
—
6.82
—
—
—
2021
28.3
6.36
6.15
45.1
74.5
22.5
2022
28.5
7.13
6.93
53
62.7
25
2023
34.1
6.46
5.82
100.5
48.4
18.9
2024
45
12.9
11.71
65.9
84.3
28.7
2025
65.2
26.3
23
46.8
101.2
40.3
— = no data for that year/metric (P/E omitted before EPS turned positive)
9-Year CAGR: Revenue +13.3% · Operating Income Surged (+43%, last 4 yrs) · Net Income +25.3% · EPS +27.5%
Source: SEC EDGAR 10-K, stockanalysis, company IR. Fiscal year (December) GAAP basis; EPS is diluted. Revenue and EPS cover 10 years (SEC); operating income, operating margin, ROE, and P/E cover the last 5 years (stockanalysis) due to data limits.
Mega-Cap Value Metric Comparison
It forms a duopoly with Novo Nordisk (NVO) in the GLP-1 obesity and diabetes market. Eli Lilly's edge is its dual-receptor agonist and deep pipeline, and with a 49.7% TTM operating margin and 102.4% ROE it ranks among pharma's best. Its P/E of 40x is high, though (source: TradingView, industry data).
Metric
★ LLY
NVO
MRK
Operating Margin
49.7%
~45%
~28%
P/E (TTM)
40.3
~20
~13
Revenue YoY Growth
+49.6%
High
Moderate
P/E and operating margin = TTM · Source: TradingView, company filings, 2026-08-07. GLP-1 is an LLY-NVO duopoly.
Key Risk Factors (from 10-K)
●
High Valuation— At ~40x P/E and P/B, much of continued GLP-1 growth is priced in; any shortfall could sink the stock.Source: TradingView
Q. What are Eli Lilly's (LLY) key value-investing metrics?P/E (TTM) 40.3, ROE 102.4%, operating margin 49.7%, net margin 33.5%, TTM revenue +49.6%, and a 9-year EPS CAGR of +27.5% (source: TradingView, company IR, as of 2026-08-07).
Q. What is GLP-1 and why does it matter?GLP-1 is a class of obesity and diabetes drugs, and Lilly's Mounjaro and Zepbound are its key growth engines. With the global obesity market projected above $100B, it is the source of the revenue and profit surge.
Q. Isn't the stock expensive?At ~40x P/E, much of the growth expectation is priced in. Some see a PEG of about 1.0–1.1 as reasonable versus growth, but a slowdown risks a re-rating. We don't offer valuation calls.